Skip to main content

Table 3 Results of univariate analysis for individual biomarkers and Mammostrat® risk score

From: Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

 

Recurrence-free survival

Distant recurrence-free survival

Overall survival

ER-positive, tamoxifen treated, node-negative

   SLC7A5

NS

NS

NS

   HTF9C

NS

NS

NS

   NRDG1

NS

1.79 (1.11 to 2.88), P = 0.015

NS

   CEACAM5

NS

NS

NS

   P53

NS

1.60 (1.01 to 2.54), P = 0.045

NS

   LMH

P = 0.016

P = 0.003

NS

   LvH

1.78 (1.08 to 2.95), P = 0.025

2.30 (1.31 to 4.05), P = 0.004

 

   LvM

1.73 (1.12 to 2.68), P = 0.014

2.01 (1.21 to 3.35), P = 0.007

 

ER-positive, tamoxifen treated

   SLC7A5

NS

NS

NS

   HTF9C

1.61 (1.04 to 2.50), P = 0.032

1.87 (1.17 to 2.98), P = 0.008

NS

   NRDG1

1.45 (1.02 to 2.05), P = 0.037

1.83 (1.26 to 2.67), P = 0.001

1.64 (1.21 to 2.21), P < 0.0005

   CEACAM5

NS

NS

NS

   P53

1.43 (1.02 to 2.01), P = 0.036

1.64 (1.13 to 2.39), P = 0.008

NS

   LMH

P = 0.003

P = 0.0001

P = 0.006

   LvH

1.80 (1.20 to 2.70), P = 0.005

2.23 (1.43 to 3.49), P = 0.0005

1.99 (1.17 to 3.41), P = 0.012

   LvM

1.65 (1.15 to 2.35), P = 0.006

1.99 (1.33 to 2.97), P = 0.0008

1.88 (1.20 to 2.96), P = 0.006

All ER-positive cases

   SLC7A5

NS

NS

NS

   HTF9C

NS

1.51 (1.01 to 2.27), P = 0.048

NS

   NRDG1

1.51 (1.13 to 2.02), P = 0.005

1.84 (1.34 to 2.52), P = 0.0001

1.82 (1.42 to 2.34), P < 0.0005

   CEACAM5

NS

NS

NS

   P53

1.39 (1.05 to 1.85), P = 0.02

1.56 (1.14 to 2.13), P = 0.005

NS

   LMH

P < 0.0001

P < 0.00001

P < 0.00001

   LvH

1.80 (1.26 to 2.57)

2.19 (1.49 to 3.24), P = 0.00008

2.16 (1.39 to 3.56), P = 0.0006

   LvM

1.78 (1.31 to 2.40), P = 0.0002

2.10 (1.49 to 2.95), P = 0.00002

2.26 (1.55 to 3.30), P = 0.00002

All cases

   SLC7A5

1.45 (1.08 to 1.95), P = 0.012

1.63 (1.19 to 2.22), P = 0.002

1.39 (1.06 to 1.80), P = 0.015

   HTF9C

1.45 (1.07 to 1.95), P = 0.015

1.57 (1.14 to 2.16), P = 0.005

1.37 (1.05 to 1.79), P = 0.021

   NRDG1

1.58 (1.25 to 2.01), P < 0.0005

1.86 (1.43 to 2.40), P < 0.0005

1.76 (1.43 to 2.17), P < 0.0005

   CEACAM5

NS

1.44 (1.03 to 2.02), P = 0.034

NS

   P53

1.57 (1.25 to 1.98), P < 0.0005

1.80 (1.40 to 2.31), P = 0.010

1.32 (1.07 to 1.63), P = 0.010

   LMH

P < 0.00001

P < 0.00001

P < 0.00001

   LvH

2.02 (1.54 to 2.64)

2.53 (1.89 to 3.40)

2.62 (1.89 to 3.63)

   LvM

1.74 (1.33 to 2.28)

2.02 (1.49 to 2.73)

2.24 (1.61 to 3.11)

  1. All individual markers analyzed as dichotomous variables. ER, estrogen receptor; LMH, P value for significance of Mammostrat® score; LvM, hazard ratio (95% confidence interval) for low-risk versus medium-risk cases classified by Mammostrat®; LvH, hazard ratio (95% confidence interval) for low-risk versus high-risk cases classified by Mammostrat®; NS, nonsignificant.